Development of liposomal salbutamol sulfate dry powder inhaler formulation

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 3, 2010, Pages 512-517

  Huang, Wen Hua ^a   Yang, Zhi Jun ^a   Wu, Heng ^a   Wong, Yuen Fan ^a   Zhao, Zhong Zhen ^a   Liu, Liang ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Dry powder inhaler; Liposome; Pulmonary delivery; Salbutamol sulfate

Indexed keywords

CRYOPROTECTIVE AGENT; LACTOSE; LACTOSE PERMEASE; LIPOSOME; LUBRICATING AGENT; MAGNESIUM STEARATE; PHOSPHOLIPID; SALBUTAMOL SULFATE; BRONCHODILATING AGENT; POWDER; SALBUTAMOL; STEARIC ACID; STEARIC ACID DERIVATIVE;

ARTICLE; ASTHMA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; ENCAPSULATION; FREEZE DRYING; GEL; IN VITRO STUDY; PARTICLE SIZE; POWDER INHALER; PRODUCTIVITY; SUSTAINED DRUG RELEASE; INHALATIONAL DRUG ADMINISTRATION; LUBRICATION; MEDICINAL CHEMISTRY; NEBULIZER; POWDER;

ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; LACTOSE; LIPOSOMES; LUBRICATION; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHOSPHOLIPIDS; POWDERS; STEARIC ACIDS;

EID: 77649229269     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.512     Document Type: Article

References (18)

1. Eagan T. M., Brøgger J. C., Eide G. E., Bakke P. S., Int. J. Tuberc. Lung Dis., 9, 603-612 (2005).
2. Nizet T. A., Broeders M. E., Folgering H. T., Respir. Med., 98, 844-850 (2004).
3. Pharmaceutical Society of Australia, "Australian Medicines Handbook," Finsbury Press, Thebarton, SA, 2000.
4. Bendas E. R., Tadros M. I., AAPS PharmSciTech, 8, E107 (2007).
5. Jantikar A., Brashier B., Maganji M., Raghupathy A., Mahadik P., Gokhale P., Gogtay J., Salvi S., Respir. Med., 101, 845-849 (2007).
6. Dhand R., Respir. Care, 50, 1331-1345 (2005).
7. Mahavir B. C., Bijay K. P., Kaustubh A. J., Ambikanandan M., Recent Pat. Drug Deliv. Formul., 1, 11-21 (2007).
8. David P., Paul J., Atkins A. S., Barry S., Adv. Drug Deliv. Rev., 26, 51-58 (1997).
9. Schreier H., Gonzales-Rothi R. J., Stecenko A. A., J. Controlled Release, 24, 209-223 (1993).
10. Shahiwala A., Misra A., AAPS PharmSciTech, 24, E482-E486 (2005).
11. Saari M., Vidgren M. T., Koskinen M. O., Turjanmaa V. M. H., Nieminen M. M., Int. J. Pharm., 181, 1-9 (1999).
12. Waldrep J. C., Gilbert B. E., Knight C. M., Black M. B., Scherer P. W., Knight V., Eschenbacher W., Chest, 111, 316-323 (1997).
13. Brandl M., Drechsler M., Bachmann D., Tardi C., Schmidtgen M., Bauer K. H., Int. J. Pharm., 170, 187-199 (1998).
14. Brandl M., Massing U., "Vesicular Phospholipid Gels," Chap. 14, 2nd ed., ed. by Torchilin V. P., Weissig V., Oxford University Press, New York, 2003, pp. 353-372.
15. Andrew S. J., "Liposome Rational Design," Chap. 11, Marcel Dekker Inc., New York, 1999.
16. Shah S. P., Misra A., Drug Deliv., 11, 247-253 (2004).
17. Shah S. P., Misra A., AAPS PharmSciTech, 5, E65 (2004).
18. Guchardi R., Frei M., John E., Kaerger J. S., Int. J. Pharm., 348, 10-17 (2008).